| 桂东.奥沙利铂、左亚叶酸钙和氟尿嘧啶化疗方案联合贝伐单抗靶向治疗转移性结肠癌的临床疗效观察[J].安徽医药,2016,20(10):1956-1958. |
| 奥沙利铂、左亚叶酸钙和氟尿嘧啶化疗方案联合贝伐单抗靶向治疗转移性结肠癌的临床疗效观察 |
| Clinical efficacy and adverse reactions of FOLFOX-6 chemotherapy combined with bevacizumab targeted therapy for metastatic colon carcinoma |
| 投稿时间：2016-02-17 |
| DOI： |
| 中文关键词: 化疗 贝伐单抗 靶向治疗 结肠癌 |
| 英文关键词: Chemotherapy Bevacizumab Targeted therapy Colon cancer |
| 基金项目: |
|
| 摘要点击次数: 2737 |
| 全文下载次数: 1120 |
| 中文摘要: |
| 目的 探索奥沙利铂(OXA)、左亚叶酸钙(LV)和氟尿嘧啶(5-Fu)组成的FOLFOX-6化疗方案与贝伐单抗靶向联合应用治疗转移性结肠癌的临床效果及不良反应。方法 将76例转移性结肠癌患者选为研究对象,并依据患者就诊顺序分成两组,对照组38例患者单用FOLFOX-6化疗方案,观察组38例患者采用FOLFOX-6化疗方案与贝伐单抗靶向联合治疗,对比两组临床疗效及不良反应情况。结果 观察组患者疾病控制率(76.32%)和总有效率(60.51%)均较对照组(44.74%、23.68%)明显增加(P<0.05)。观察组患者无进展生存期(9.87±1.23)月和总生存期(24.34±2.04)月均较对照组(6.45±1.10)月、(15.12±1.62)月明显延长(P<0.05)。两组患者主要不良反应胃肠道反应、神经毒性、手足综合征、骨髓抑制发生率比较,差异无统计学意义(P＞0.05)。结论 FOLFOX-6化疗方案与贝伐单抗靶向联合应用治疗转移性结肠癌近期和远期疗效均优于单用化疗方案治疗,且安全性较高,值得临床借鉴和推广应用。 |
| 英文摘要: |
| Objective To explore the clinical efficacy and adverse reactions of FOLFOX-6 chemotherapy combined with bevacizumab targeted therapy for metastatic colon carcinoma.Methods Seventy-six cases of metastatic colon cancer patients hospitalized were selected as the research subjects,and they were assigned into two groups on the basis of the consultation order.The 38 patients in the control group used FOLFOX-6 chemotherapy alone,while the 38 patients in the observation group used FOLFOX-6 chemotherapy combined with bevacizumab targeted therapy.Clinical curative effect and adverse reaction were compared between the two groups.Results The DCR (76.32%) and RR (60.51%) in the observation group were significantly higher than those in the control group(44.74%,23.68%) (P<0.05).The PFS (9.87±1.23) months and OS (24.34±2.04) months of the observation group were significantly longer than (6.45±1.10) months,(15.12±1.62) months in the control group(P<0.05).There was no significant difference in the incidences of gastrointestinal reactions,neurotoxicity,hand foot syndrome and bone marrow suppression between the two groups (P>0.05).Conclusions FOLFOX-6 chemotherapy combined with bevacizumab targeted therapy in the treatment of metastatic colon carcinoma has a better short-term and long-term therapeutic effect and higher security than the single chemotherapy,which is worthy of clinical reference and promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
